LivaNova (NASDAQ:LIVN) Price Target Lowered to $76.00 at Robert W. Baird

LivaNova (NASDAQ:LIVN) had its target price decreased by Robert W. Baird from $78.00 to $76.00 in a report released on Thursday morning,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

Several other equities analysts have also recently weighed in on LIVN. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $66.00 target price on shares of LivaNova in a research note on Friday, January 9th. Barclays raised their price objective on LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a research report on Thursday. Needham & Company LLC increased their price target on LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of LivaNova in a research note on Friday, March 27th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $85.00 price target on shares of LivaNova in a report on Thursday, February 19th. Seven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.22.

LivaNova Trading Up 7.0%

Shares of LIVN stock opened at $70.93 on Thursday. LivaNova has a 52-week low of $41.01 and a 52-week high of $71.92. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.16 and a current ratio of 1.33. The firm has a market capitalization of $3.90 billion, a PE ratio of 36.37 and a beta of 0.82. The stock has a fifty day simple moving average of $64.01 and a two-hundred day simple moving average of $62.15.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.85 by $0.13. The business had revenue of $362.26 million for the quarter, compared to the consensus estimate of $346.05 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The business’s revenue was up 14.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.88 earnings per share. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, analysts predict that LivaNova will post 3.66 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in LIVN. Hantz Financial Services Inc. boosted its stake in shares of LivaNova by 159.9% during the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after purchasing an additional 267 shares in the last quarter. State of Wyoming purchased a new stake in LivaNova during the second quarter worth $31,000. EverSource Wealth Advisors LLC boosted its position in LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after acquiring an additional 639 shares in the last quarter. Quarry LP purchased a new position in shares of LivaNova in the 3rd quarter valued at $36,000. Finally, UMB Bank n.a. increased its holdings in shares of LivaNova by 63.0% in the 3rd quarter. UMB Bank n.a. now owns 792 shares of the company’s stock valued at $41,000 after acquiring an additional 306 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.